Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 25, 2021
- Accepted in final form June 14, 2021
- First Published July 22, 2021.
Author Disclosures
- Enric Monreal, MD,
- Susana Sainz de la Maza, MD (susanasmc85{at}hotmail.com),
- Lucienne Costa-Frossard, MD (lufrossard{at}yahoo.es),
- Paulette Walo-Delgado, MD (pauletteesperanz.walo{at}salud.madrid.org),
- Javier Zamora, PhD (javierza{at}gmail.com),
- José Ignacio Fernández-Velasco, MSc (jfvelasco{at}salud.madrid.org),
- Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
- Mercedes Espiño, PhD (mercedes.espino{at}salud.madrid.org),
- Daniel Lourido, MD (louridodaniel{at}hotmail.com),
- Paloma Lapuente, MD (paloma.lapuente{at}salud.madrid.org),
- Inmaculada Toboso, PhD (inma.toboso.delamo{at}gmail.com),
- José Carlos Álvarez-Cermeño, PhD (josecarlos.alvarez{at}salud.madrid.org),
- Jaime Masjuan, PhD (jaime.masjuan{at}salud.madrid.org) and
- Luisa María Villar, PhD (luisamaria.villar{at}salud.madrid.org)
- Enric Monreal, MD,
(1) Sanofi-Genzyme
NONE
(1) Biogen, funding for travel and speak to conference (2) Roche, funding for travel to conference (3) Almirall, funding for travel to conference (4) Sanofi-Genzyme, funding for travel to conference (5) Novartis, funding for travel to conference (6) Merck, funding for travel to conference
NONE
(1) Lymphocytes subsets ratio to predict autoimmunity in patients treated with Alemtuzumab.
NONE
NONE
NONE
NONE
(1) Merck, promotional campaign
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Susana Sainz de la Maza, MD (susanasmc85{at}hotmail.com),
(1) Almirall (Comercial entity) (2) Merck (Commercial entity) (3) Sanofi-Genzyme (Commercial entity)
NONE
(1) Biogen. Commercial entity. Speaker honoraria. (2) Merck. Commercial entity. Speaker honoraria. (3) Roche. Commercial entity. Speaker honoraria. (4) Sanofi-Genzyme. Commercial entity. Speaker honoraria. (5) Teva. Commercial entity. Speaker honoraria.
NONE
17 382 331.1. Method for monitoring and predicting the efficacy of treatment in a multiple sclerosis patient España. 20/06/2017. FIBio-HRC.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lucienne Costa-Frossard, MD (lufrossard{at}yahoo.es),
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
Editorial Board Member in American Journal of Psychiatry and Neuroscience
NONE
NONE
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paulette Walo-Delgado, MD (pauletteesperanz.walo{at}salud.madrid.org),
NONE
NONE
NONE
NONE
Patent No. 20382988.2 - 1118 Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Javier Zamora, PhD (javierza{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José Ignacio Fernández-Velasco, MSc (jfvelasco{at}salud.madrid.org),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: RD16/0015/0001, 2019-2021 (2)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: PI18/00572, 2017-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mercedes Espiño, PhD (mercedes.espino{at}salud.madrid.org),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Lourido, MD (louridodaniel{at}hotmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paloma Lapuente, MD (paloma.lapuente{at}salud.madrid.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inmaculada Toboso, PhD (inma.toboso.delamo{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José Carlos Álvarez-Cermeño, PhD (josecarlos.alvarez{at}salud.madrid.org),
Genzyme, Araclon Biotech
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jaime Masjuan, PhD (jaime.masjuan{at}salud.madrid.org) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa María Villar, PhD (luisamaria.villar{at}salud.madrid.org)
Genzyme, Biogen, Merck, Novartis
NONE
Biogen: Funding for travel or speaker honorariaMerck: Funding for travel or speaker honorariaNovartis: Funding for travel or speaker honorariaGenzyme: Funding for travel or speaker honorariaRoche: Funding for travel or speaker honoraria
NONE
Biomarker for selecting good responders to IFN beta in multiple sclerosis
NONE
NONE
I have received payment for consultancies fromBiogen Idec, Merck, Novartis, (Commercial entities)
NONE
NONE
NONE
Genzyme; Merck; Biogen; Roche
Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (ISCIII). Grant N. PI18/00572 for the research in MS. Years 2019-2021
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (E.M., S.S.d.l.M., L.C.-F., J.C.Á.-C., J.M.), and Department of Immunology (P.W.-D., J.I.F.-V., N.V., M.E., P.L., I.T., L.M.V.), Hospital Universitario Ramón y Cajal, REEM, IRYCIS; Clinical Biostatistics Unit (J.Z.), Hospital Universitario Ramón y Cajal, IRYCIS, CIBERESP, Madrid, Spain; Institute of Metabolism and System Research (J.Z.), University of Birmingham, United Kingdom; and Department of Radiology (D.L.), Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
- Correspondence
Dr. Monreal enricmonreal{at}outlook.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
A reassessment of the plateauing relationship between T2 lesion load and disability in MSMaria Pia Sormani, Marco Rovaris, Giancarlo Comi et al.Neurology, September 30, 2009 -
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021 -
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Articles
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosisJ. Kuhle, D. Leppert, A. Petzold et al.Neurology, February 23, 2011